Tag: sclc
-
Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office.
-
Andarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto, Japan.
-
Andarix Pharmaceuticals to Present at Chinese Biopharmaceutical Association Conference, USA
Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced that its Chief Executive Officer, Chris Adams, will present at the Chinese Biopharmaceutical Association (CBA) USA conference. The CBA conference will take place on June 9, 2018 in Gaithersburg, MD.
-
Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018.
-
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The data will be presented at…
-
Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017. Conference location and agenda information are available at the Precision Lung Cancer Conference.
-
Andarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting
Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO) conference in Chicago, IL June 2-6 2017.
-
Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study
In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using Rhenium Re 188 P2045, a radiolabeled somatostatin analog. 25 Patients received the imaging dose of 10uCi of Re188 and 265ng of peptide by intravenous injection. Patients were selected based on high SSTR expression levels…
-
Andarix Selected to Present at Prominent Drug Development Conferences
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at two upcoming conferences in Boston, MA this fall. Both conferences are invitation only for presenting companies, and showcase leading drug development organizations working to advance groundbreaking…
-
Andarix Selected to Present at Orphan Drug Congress
ANDARIX Pharmaceuticals, a clinical stage company developing a targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the World Orphan Drug Conference in Washington, DC on April 23, 2015. Conference location and agenda information are available at the World Orphan Drug Congress. Andarix’ lead development…